Heritage announces availability of Prochlorperazine Edisylate Injection

NewsGuard 100/100 Score
Jan 16 2014

Heritage Pharmaceuticals Inc. ("Heritage") announced the immediate availability of Prochlorperazine Edisylate Injection in the 5mg/mL strength. This product is the AP rated generic equivalent to the former brand Compazine and adds to Heritage's growing portfolio of generic injectable prescription products. According to IMS data for the twelve-months ended December 2013, the U.S. market for Prochlorperazine Edisylate Injection approximated $5.5 million.

Source:

Heritage Pharmaceuticals Inc.

Posted in: Medical Condition News | Healthcare News | Pharmaceutical News

Tags: , , , , , , ,

Comments (0)

Suggested Reading

Research quantifies impact of childhood obesity on long-term health and life expectancy
Common HIV drugs linked to reduced Alzheimer's disease risk
Study highlights global fertility decline and its implications for the future
Sensing a Healthier Future with Sustainable Nanomaterials and Biosensors
Lancet Commission predicts sharp increase in global prostate cancer cases
Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
Extended CPAP treatment boosts lung development in premature infants
New urine-based test improves identification of high-grade prostate cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Georgetown study raises concerns over aspirin's role in breast cancer treatment